A Phase 3b, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants with Moderate-to-Severe Face and Neck Atopic Dermatitis

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-525133-31-00

Enrollment

123

Registered

2026-09-22

Start date

Unknown

Completion date

Unknown

Last updated

2026-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Face and Neck Atopic Dermatitis

Brief summary

Percentage of participants achieving an IGA score of 0 or 1 and a reduction ≥2 points from Baseline at Week 16

Detailed description

1. Percentage of participants with DLQI ≥4 points at Baseline achieving DLQI ≥4-point improvement from Baseline at Week 16, 2. Percentage change from Baseline to Week 16 in SCORing AD (SCORAD)

Interventions

DRUGSolution for injection

DRUGcontaining the same excipients as the respective active lebrikizumab. Identical in appearance to test IMP. Supplied as a sterile PFS NSD.

DRUGEbglyss 250 mg solution for injection in pre-filled syringe

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage of participants achieving an IGA score of 0 or 1 and a reduction ≥2 points from Baseline at Week 16	—

Secondary

Measure	Time frame
1. Percentage of participants with DLQI ≥4 points at Baseline achieving DLQI ≥4-point improvement from Baseline at Week 16, 2. Percentage change from Baseline to Week 16 in SCORing AD (SCORAD)	—

Outcome results

None listed

Source: EU CTIS · Data processed: Sep 26, 2026